These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 3713372)

  • 41. Immunoadjuvant activities of synthetic 6-O-acyl-N-acetylmuramyl-L-alanyl-D-isoglutamine with special reference to the effect of its administration with liposomes.
    Kotani S; Kinoshita F; Morisaki I; Shimono T; Okunaga T; Takada H; Tsujimoto M; Watanabe Y; Kato K; Shiba T; Kusumoto S; Okada S
    Biken J; 1977 Dec; 20(3-4):95-103. PubMed ID: 614856
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Acute toxicity of muroctasin in mice, rats and dogs.
    Ono Y; Iwasaki T; Furuhama K; Onodera T
    Arzneimittelforschung; 1988 Jul; 38(7A):1022-4. PubMed ID: 3190794
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Activation of alveolar macrophage tumoricidal activity and eradication of experimental metastases by freeze-dried liposomes containing a new lipophilic muramyl dipeptide derivative.
    Phillips NC; Moras ML; Chedid L; Lefrancier P; Bernard JM
    Cancer Res; 1985 Jan; 45(1):128-34. PubMed ID: 3838084
    [TBL] [Abstract][Full Text] [Related]  

  • 44. MDP-Lys(L18), a lipophilic derivative of muramyl dipeptide, inhibits the metastasis of haematogenous and non-haematogenous tumours in mice.
    Yoo YC; Saiki I; Sato K; Azuma I
    Vaccine; 1994 Feb; 12(2):175-60. PubMed ID: 8147100
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Production of colony-stimulating factor from macrophages by muroctasin.
    Yamaguchi F; Akahane K; Takashi T; Tsukada W
    Arzneimittelforschung; 1988 Jul; 38(7A):983-6. PubMed ID: 3263870
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Adjuvant activity of muramyl dipeptide derivatives to enhance immunogenicity of a hantavirus-inactivated vaccine.
    Yoo YC; Yoshimatsu K; Koike Y; Hatsuse R; Yamanishi K; Tanishita O; Arikawa J; Azuma I
    Vaccine; 1998; 16(2-3):216-24. PubMed ID: 9607033
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Studies on the stability of muroctasin and degradation products built under extreme conditions.
    Moroi R; Yamazaki K; Hirota T; Watanabe S; Oki M; Toriyama M; Ichinohe A; Kataoka K
    Arzneimittelforschung; 1988 Jul; 38(7A):959-68. PubMed ID: 3190803
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Induction of colony-stimulating factor and stimulation of stem cell proliferation by injection of muroctasin.
    Yamaguchi F; Akasaki M; Tsukada W
    Arzneimittelforschung; 1988 Jul; 38(7A):980-3. PubMed ID: 3263869
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Subacute toxicity of muroctasin in mice and dogs.
    Ono Y; Iwasaki T; Sekiguchi M; Onodera T
    Arzneimittelforschung; 1988 Jul; 38(7A):1024-7. PubMed ID: 3190795
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Adjuvant activity of 6-O-acyl-muramyldipeptides to enhance primary cellular and humoral immune responses in guinea pigs: dose-response and local reactions observed with selected compounds.
    Tsujimoto M; Kotani S; Shiba T; Kusumoto S
    Infect Immun; 1986 Sep; 53(3):517-21. PubMed ID: 3744549
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Induction of colony-stimulating activity (CSA) by a synthetic muramyl peptide (MDP): synergism with LPS and activity in C3H/HeJ mice and in endotoxin-tolerized mice.
    Galelli A; Chedid L
    J Immunol; 1986 Nov; 137(10):3211-5. PubMed ID: 3490515
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Influence of indomethacin on various immunopharmacological effects of muramyl dipeptide (MDP).
    Parant M; Riveau G; Chedid L
    Agents Actions Suppl; 1980; 7():33-40. PubMed ID: 6941684
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Chronic toxicity of muroctasin in mice.
    Ono Y; Sekiguchi M; Aihara K; Onodera T
    Arzneimittelforschung; 1988 Jul; 38(7A):1028-30. PubMed ID: 3190796
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Enhancement of endotoxin activity by muramyldipeptide.
    Takada H; Yokoyama S; Yang S
    J Endotoxin Res; 2002; 8(5):337-42. PubMed ID: 12537692
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Distribution and fate of free and liposome-encapsulated [3H]nor-muramyl dipeptide and [3H]muramyl tripeptide phosphatidylethanolamine in mice.
    Fogler WE; Wade R; Brundish DE; Fidler IJ
    J Immunol; 1985 Aug; 135(2):1372-7. PubMed ID: 4008926
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Modulation of natural killer activity by muramyl peptides: relationship with adjuvant and anti-infectious properties.
    Le Garrec Y; Morin A
    Nat Immun Cell Growth Regul; 1987; 6(2):65-76. PubMed ID: 2439906
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Role of tumor necrosis factor in lethality during endotoxic shock in mice presensitized with serum of tumor-bearing mice].
    Shapoval AI
    Biull Eksp Biol Med; 1993 Jan; 115(1):57-9. PubMed ID: 8054581
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Chemical structure and biological activity relationship of bacterial cell walls and muramyl peptides.
    Kotani S; Tsujimoto M; Koga T; Nagao S; Tanaka A; Kawata S
    Fed Proc; 1986 Oct; 45(11):2534-40. PubMed ID: 3758371
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Production of interleukin-6 from macrophages by MDP-Lys (L 18), romurtide.
    Shimoda K; Okamura S; Harada N; Omori F; Niho Y
    Res Commun Chem Pathol Pharmacol; 1990 Dec; 70(3):289-96. PubMed ID: 2093210
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Therapeutic efficacy of kanamycin and clofazimine combined with muramyl dipeptide against Mycobacterium intracellulare infection induced in mice].
    Tomioka H; Sato K; Saito H
    Kekkaku; 1991 Dec; 66(12):811-7. PubMed ID: 1784098
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.